The aim of this study was to identify hereditary and acquired risk-factors as they are related to the occurrence of stroke in children. We identified 21 children with stroke. A search of the Factor V Leiden mutation, the Factor II G20210A variant, and the thermolabile variant of methylenetetrahydrofolate reductase was performed in patients and in a control group (n = 115). We identified risk fa...

BACKGROUND Factor V Leiden mutation (Arg506Gln) increases the likelihood of venous thrombosis; it may also have a positive effect through facilitation of embryo implantation. This may manifest itself as a reduced time to pregnancy (increased fecundity) and fewer miscarriages in the first trimester. METHODS From March 1999 onwards, consecutive patients with a first venous thrombosis (VT) were ...

AIM To determine the prevalence of factor V Leiden mutation in patients with different presentation of venous thromboembolic disease and healthy individuals in the Republic of Macedonia. METHODS The retrospective case control study involved 190 patients with venous thromboembolic disease and 200 healthy individuals, who were screened for the presence of factor V Leiden mutation, using a polym...

To determine whether factor V Leiden (FVL) and/or prothrombin gene G20210A mutation (PT20210A) are risk factors for venous thromboembolism (VTE) in Argentinean children. One hundred and thirty consecutive children with VTE were prospectively assisted at a single centre. Blood samples were available from 110 of them for detailed haematological analysis. The prevalence of both mutations was compa...

The aim of this review was to compile published data on factor V 1691 G-A alteration in a healthy Turkish population and also to stimulate the reporting of unpublished data, in order to create a map for factor V Leiden (FVL) in Turkey. From a total of 4276 healthy individuals from 26 different centers of Turkey, 345 FVL carriers (7.9%) were determined. FVL was strikingly high among newborns fro...

s of all RAND Health publications and full text of many research documents can be found on the RAND Health web site at www.rand.org/health. The RAND Corporation is a nonprofi t research organization providing objective analysis and effective solutions that address the challenges facing the public and private sectors around the world. RAND’s publications do not necessarily refl ect the opinions ...

introduction: normal homeostasis system has several inhibitor mechanisms in front of the amplifier’s natural clotting enzyme to prevent fibrin clots in the vessels. the main inhibitors of coagulation pathway are antithrombin (at), protein c and protein s. patients with hereditary deficiency of coagulation inhibitors are susceptible to venous thromboembolism (vte). one of the major clinical mani...

background: inherited thrombophilic gene polymorphisms have been related to the pathogenesis of venous thromboembolism and its outcomes. considering the scarcity of data on the frequency of the thrombophilic gene polymorphisms in iranian populations, the aim of this study was to assess such polymorphisms in healthy individuals. materials and methods: this cross-sectional study was performed on ...

BACKGROUND Factor V Leiden has been reported in 2%-30% of patients with portal vein thrombosis. This wide variation makes it difficult to assess the importance of factor V Leiden as a predisposing factor. METHODS Factor V Leiden was determined by restriction fragment length polymorphism in 112 patients with portal vein thrombosis, 104 with deep vein thrombosis and 98 control subjects. RESUL...

Factor V Leiden is a common genetic mutation that predisposes its carriers to venous thromboembolism. When combined with the hypercoagulable state that is characteristic of pregnancy, there is an increased risk of severe and recurrent pregnancy complications. Factor V Leiden is the most common cause of primary and recurrent venous thromboembolism in pregnancy. Factor V Leiden carriage has consi...